Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.84 |
| ▸ | RECQL | P46063 | 3/20 | 0.84 |
| ▸ | MEN1 | O00255 | 2/20 | 0.84 |
| ▸ | MAPT | P10636 | 2/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | POLB | P06746 | 2/20 | 0.84 |
| ▸ | APEX1 | P27695 | 2/20 | 0.84 |
| ▸ | POLH | Q9Y253 | 2/20 | 0.84 |
| ▸ | MMP1 | P03956 | 1/20 | 0.84 |
| ▸ | GAA | P10253 | 1/20 | 0.84 |
| ▸ | HTT | P42858 | 1/20 | 0.84 |
| ▸ | BLM | P54132 | 1/20 | 0.84 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.82 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.82 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825010 | 1.00 | PLG (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| SCHEMBL12189555 | 0.93 | PLG (0.86) | PLGNOX4KDM4ERECQLMEN1 | |
| 3-O-Methylquercetin SCHEMBL380558 | 0.91 | POLH (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| 3-O-Methylquercetin SCHEMBL29897544 | 0.91 | POLH (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| Pachypodol SCHEMBL39280 | 0.90 | ABCG2 (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| SCHEMBL15635393 | 0.90 | PLG (0.82) | PLGNOX4KDM4ERECQLMEN1 | |
| Pachypodol SCHEMBL29929114 | 0.90 | ABCG2 (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| Ayanin SCHEMBL1252843 | 0.90 | ABCG2 (1.00) | PLGNOX4KDM4ERECQLMEN1 | |
| SCHEMBL4649968 | 0.90 | CYP3A4 (0.88) | PLGNOX4KDM4ERECQLMEN1 | |
| SCHEMBL30131217 | 0.90 | CYP3A4 (0.88) | PLGNOX4KDM4ERECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3655015-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | UNIV COLORADO REGENTS (US) | 2024-02-21 | — | — | EP | claimed |
| CN-116953141-A | Method for constructing characteristic spectrum of siegesbeckia herb preparation with different primordia | 北京康仁堂药业有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | TSINGHUA UNIVERSITY (CN) | 2023-07-27 | — | — | US | claimed |
| CN-113730475-A | Application of physalis pubescens persistent calyx extract | 锦州医科大学 | 2021-12-03 | — | — | CN | claimed |
| CN-109856264-B | Method for detecting content of effective components in blumea balsamifera medicinal material | 遵义医科大学 | 2021-09-07 | — | — | CN | claimed |
| CN-111447940-A | Compositions and methods for preventing or treating radiation-induced bystander effects caused by radiation or radiotherapy | 科罗拉多大学评议会 | 2020-07-24 | — | — | CN | claimed |
| EP-3655015-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | The Regents of the University of Colorado (US) | 2020-05-27 | — | — | EP | claimed |
| US-20200155502-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-05-21 | — | — | US | claimed |
| US-10383841-B2 | Antimicrobial and antiinflammatory composition | DENOVASTELLA AB (SE) | 2019-08-20 | — | — | US | claimed |
| CN-109856264-A | The detection method of active constituent content in Blumea balsamifera medicinal material | 遵义医学院 | 2019-06-07 | — | — | CN | claimed |
| WO-2004037180-A2 | COMPOSITIONS THAT TREAT OR INHIBIT PATHOLOGICAL CONDITIONS ASSOCIATED WITH INFLAMMATORY RESPONSE | METAPROTEOMICS, LLC (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040086580-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | META PROTEOMICS, LLC | 2004-05-06 | — | — | US | claimed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | claimed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | claimed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | claimed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | claimed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | claimed |
| US-4774229-A | ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-09-27 | — | — | US | claimed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| WO-1987006833-A1 | MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE | CHEMEX PHARMACEUTICALS, INC. (US) | 1987-11-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086580-A1 | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response | HPGDS, TPSB2, TPSG1 | PLG 1832/4885NOX4 2437/4885KDM4E 4291/4885 |
| US-20230233517-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | PLG 740/4885NOX4 682/4885KDM4E 157/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | PLG 3451/4885NOX4 1866/4885KDM4E 893/4885 |
| US-20200155502-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | CTSE, CTSB, ATG4B | PLG 740/4885NOX4 682/4885KDM4E 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.